BCL2 and neoplasm: While the intermediate level of TZB treatment attains the maximal ET due to up-regulated Bcl-2 expression and sustained apoptosis activity (the case (ii)), high doses of TZB leads to lower anti-tumor efficacy from the large population of CSCs (the case (iii)).